Novolizer (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Novolizer, is a long‑acting β2‑adrenergic agonist (LABA) presented as a dry powder inhaler for inhalation use. It provides bronchodilation for the management of asthma and chronic obstructive pulmonary disease (COPD) in adult patients, delivering precise doses directly to the lungs to support long‑term control of airway symptoms.

GNH USA supplies Novolizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novolizer, containing formoterol, is a long‑acting bronchodilator used in the management of obstructive airway diseases.

- Asthma: improves lung function, reduces symptoms and decreases the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances airflow, improves exercise tolerance and lowers the risk of flare‑ups. - Exercise‑induced bronchoconstriction: provides prophylactic bronchodilation to prevent airway narrowing during physical activity.

Novolizer may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Tremor: mild shaking, often of the hands. - Headache: transient, mild to moderate intensity. - Throat irritation: discomfort or soreness after inhalation. - Cough: occasional dry cough following dose administration.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmias: irregular heart rhythms, especially in susceptible individuals. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hypokalemia: low blood potassium levels that may cause muscle weakness.

Before prescribing Novolizer, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate patients with known heart disease. - Prescription adherence: use only as directed by a healthcare professional. - Monitor asthma control: watch for worsening symptoms or increased rescue inhaler use. - Hypersensitivity check: avoid in patients with known allergy to formoterol or excipients. - Use with caution in severe COPD: assess risk of adverse events. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Novolizer can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may diminish bronchodilator effect. - Monoamine oxidase inhibitors (MAOIs): increase risk of cardiovascular events. - Diuretics: may exacerbate hypokalemia. - Other long‑acting β2‑agonists: increase risk of overdose and side effects.

Moderate Interactions (Monitor Closely): - Inhaled corticosteroids: potential increased risk of pneumonia. - Theophylline: may raise plasma theophylline concentrations. - Anticholinergic agents: possible additive bronchial effects. - ACE inhibitors: monitor for cough or angioedema.